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Background: Computational methods for mining of biomedical literature can be useful in augmenting manual
searches of the literature using keywords for disease-specific biomarker discovery from biofluids. In this work, we
develop and apply a semi-automated literature mining method to mine abstracts obtained from PubMed to
discover putative biomarkers of breast and lung cancers in specific biofluids.
Methodology: A positive set of abstracts was defined by the terms ‘breast cancer’ and ‘lung cancer’ in conjunction
with 14 separate ‘biofluids’ (bile, blood, breastmilk, cerebrospinal fluid, mucus, plasma, saliva, semen, serum, synovial
fluid, stool, sweat, tears, and urine), while a negative set of abstracts was defined by the terms ‘(biofluid) NOT breast
cancer’ or ‘(biofluid) NOT lung cancer.’ More than 5.3 million total abstracts were obtained from PubMed and
examined for biomarker-disease-biofluid associations (34,296 positive and 2,653,396 negative for breast cancer;
28,355 positive and 2,595,034 negative for lung cancer). Biological entities such as genes and proteins were tagged
using ABNER, and processed using Python scripts to produce a list of putative biomarkers. Z-scores were calculated,
ranked, and used to determine significance of putative biomarkers found. Manual verification of relevant abstracts
was performed to assess our method’s performance.
Results: Biofluid-specific markers were identified from the literature, assigned relevance scores based on frequency
of occurrence, and validated using known biomarker lists and/or databases for lung and breast cancer [NCBI’s
On-line Mendelian Inheritance in Man (OMIM), Cancer Gene annotation server for cancer genomics (CAGE), NCBI’s
Genes & Disease, NCI’s Early Detection Research Network (EDRN), and others]. The specificity of each marker for a
given biofluid was calculated, and the performance of our semi-automated literature mining method assessed for
breast and lung cancer.
Conclusions: We developed a semi-automated process for determining a list of putative biomarkers for breast
and lung cancer. New knowledge is presented in the form of biomarker lists; ranked, newly discovered
biomarker-disease-biofluid relationships; and biomarker specificity across biofluids.
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The amount of scientific information has become over-
whelmingly abundant, providing querying difficulties for
scientists and physicians. While many data mining and lit-
erature mining methods have been described [1-11], new
and innovative methods are highly desired. Articles have* Correspondence: rmj12@pitt.edu
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unless otherwise stated.been written about drawing implicit connections from sep-
arate literatures [12-15], and many unidentified connec-
tions exist within publicly available material. Identifying
putative disease biomarkers may lead to new connections
between biofluids and diseases being discovered.
It is known that false positive elimination from text
mining findings can be aided by the use of negative ab-
stract sets, which are abstracts that are specifically not
about the entity or relationship of interest. It is also im-
portant to examine all abstracts, both positive andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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statistical significance measures can be accurately calcu-
lated. However, it does not seem that negative abstract
sets are discussed in detail.
A literature search identified several biomedical text
mining papers describing the use of a negative set of ab-
stracts [2,16-19]. Implementations of negative sets of ab-
stracts seem to be described far less than would be
expected. Adamic et al. [2] presented a statistical approach
for finding gene-disease relations. The authors described a
frequency of occurrence count and an expected number
of relevant abstracts vs. a random set. Gene pairs and gene
symbol disambiguation results were compared to a human
edited breast cancer gene database.
Al-Mubaid, et al.’s method [16] for discovering protein-
to-disease associations from MEDLINE abstracts employed
a protein and disease name dictionary and “positive” and
“negative” sets of abstracts. The positive set consisted of
abstracts relevant to a given disease, as determined by a
PubMed keyword search; the negative set contained a ran-
dom set of abstracts that did not mention the disease. The
method identified proteins that were relevant to the dis-
ease by comparing the frequency distributions of protein
names in the positive set and the overall set, which was
the union of the positive and negative sets, and selected
those proteins for which the distributions were signifi-
cantly different statistically.
Andrade [17] was interested in annotating biological
function of protein sequences. In this article, the ‘treat-
ment of text with statistical methods’ was discussed.
Their approach estimated the word significance from a
given set of protein family abstracts by comparing each
word’s abundance and distribution in a background set
of varying protein family abstracts.
Younesi, et al. [18,19] divided the biomarker termin-
ology into six concept classes (clinical management; diag-
nostics; prognosis; statistics; evidence; and antecedent). By
including this extra level of restriction, the authors were
able to significantly reduce the number of retrieved rele-
vant documents. Frequency and entropy ranking methods
were used for acquired genelists, with frequency ranking
performing better overall, with their method.
Individual biofluids have been characterized; [20-25]
however, we have found only one comprehensive compari-
son of more than a few biofluids. Alterovitz et al. [26] com-
pared 10 biofluid proteomes to 16 tissue proteomes to
determine tissue function, and tissue-specific candidate
biomarkers that could be found in a given biofluid. Gene
Ontology (GO); [27,28] http://www.geneontology.org/, was
used for functionality mapping, NCBI’s Online Mendelian
Inheritance in Man (OMIM); [29] http://www.ncbi.nlm.
nih.gov/omim/, for disease mapping, the Pharmacogenom-
ics Knowledge Base (PharmGKB); [30] https://www.
pharmgkb.org/, for drug mapping, and a relative entropymeasure was the scoring method of choice. PubMed co-
citation frequencies were used to determine the overall
quality of the candidate biomarkers.
Comparisons such as those described above have the
potential to reveal critical knowledge as to which bio-
markers for a disease may be detected in a given bio-
fluid. As some biofluids are more easily obtainable than
others, elimination of invasive sampling procedures is
highly desirable. However, details describing which po-
tential biomarkers can be obtained in given biofluids are
not clearly defined.
In this paper, we developed a semi-automated process
for determining a list of putative biomarkers for breast
and lung cancers, with a putative biomarker being de-
scribed as a ‘gene’ or ‘protein’. 5.3 million PubMed
abstracts were analysed for biomarker-disease associa-
tions (34,296 positive and 2,653,396 negative for breast
cancer; 28,355 positive and 2,595,034 negative for lung
cancer). The abstract sets were further stratified among
14 biofluids. New knowledge is provided in the form of
known disease biomarker lists, ranked newly discovered
biomarker-disease-biofluid relationships, and biomarker
specificity across biofluids. On average, (see Additional
file 1) we expect true positive rates for new discoveries
to be 87.5% for breast cancer, and 71.59% for lung can-
cer. These biomarker-disease association and accom-
panying z-scores will be used as informative prior values
in future disease modeling activities.
Methodology
Automation
Python scripts were developed to reduce the amount of
manual effort needed to achieve final scores for each po-
tential biofluid biomarker, and to eliminate manual er-
rors. Figure 1 shows a flowchart that summarizes the
experimental methodology used.
Information retrieval
For retrieving abstracts related to breast and lung cancer,
a PubMed query was performed using the following
limits: Abstracts, English, and Human. Query results for
diseases-biofluid can be found in Table 1 (see Additional
file 2 for Biofluid synonyms used). An abstract consists
of journal entry information, title, authors, affiliations,
text, copyright information, and PubMed ID. The follow-
ing sets of abstracts were obtained using the selected
criteria from the positive and/or negative queries (defined
below).
 Positive Abstract Sets
A positive abstract set is defined as the set of
abstracts obtained by using the following
combination of keywords, ‘breast cancer AND
(biofluid)’, e.g. breast cancer AND plasma, or ‘lung
Figure 1 Semi-automated flowchart of the information retrieval process. Python scripts were written to process text files. ABNER was used
for tagging biological entities, and the z-score calculation was performed using Microsoft Excel.
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all positive abstract sets will be called “positive sets”
for brevity. Positive set queries were performed on
4-29-2013 for breast cancer and 5-2-2013 for lung
cancer. The underlying assumption being made is
that any possible biomarker mentioned in these
abstract sets is related to both the disease and
the biofluid. Queries were returned from PubMed
as large text files, and Python scripts were
implemented to process the files. Negative Abstract Sets
We define a negative abstract set as a set of abstracts
returned using the keywords ‘(biofluid) NOT breast
cancer’ or ‘(biofluid) NOT lung cancer’. From this
point forward, all negative abstract sets will be called
“negative sets” for the entirety of this article. Negative
set queries were performed on 4-29-2013 for breast
cancer and 5-2-2013 for lung cancer. Queries were
returned from PubMed as large text files, and Python
scripts were implemented to process the files.
Table 1 Size of the abstract sets returned from queries of
breast and lung cancer
Breast cancer Lung cancer
Biofluid Positives Negatives Biofluid Positives Negatives
Bile 360 40,250 Bile 328 40,290
Blood 18,939 1,540,721 Blood 15,710 1,522,046
Breastmilk 1,047 17,874 Breastmilk 99 18,834
CSF 252 42,711 CSF 298 42,676
Mucus 116 25,122 Mucus 1,445 23,801
Plasma 4,327 342,415 Plasma 3,227 343,678
Saliva 149 22,694 Saliva 86 22,770
Semen 40 12,956 Semen 9 12,989
Serum 7,410 415,218 Serum 6,029 412,897
SF 18 7,699 SF 18 7,671
Stool 123 37,574 Stool 90 37,619
Sweat 321 11,079 Sweat 88 11,673
Tears 40 11,651 Tears 10 11,673
Urine 1,154 125,462 Urine 918 86,776
Total 34,296 2,653,396 Total 28,355 2,595,034
CSF = cerebrospinal fluid; SF = synovial fluid.
Jordan et al. Journal of Clinical Bioinformatics 2014, 4:13 Page 4 of 9
http://www.jclinbioinformatics.com/content/4/1/13Filtering information
Python scripts were developed to remove unwanted
punctuation and other unwanted information from the
abstracts.
Named entity recognition
ABNER [31] (A Biomedical Named Entity Recognizer;
http://pages.cs.wisc.edu/~bsettles/abner/) v1.5 was used
to tag mentions of proteins, DNA, RNA, cell lines, and
cell types in the positive and negative sets. Version 1.5
trains on the NLBPA and BioCreative corpora. Reported
performance measures for ABNER are in the range of
65.9-77.8 for protein recall and 68.1-74.5 for protein pre-
cision. Our method utilizes entities tagged as “Protein”,
“DNA”, and “RNA”. A batch tagging process is available
and proved to be extremely useful.
Entity extraction
Python scripts were developed to produce a list of
tagged entities from the ABNER results file (.sgml), re-
move unwanted characters, tags, tagged entries, and du-
plicate putative biomarkers from the list, and to tally the
final count of each biological entity found. PubMed
identifiers were retained for tracking and manual verifi-
cation purposes.
Dictionary
A file named Protein Nomenclature was downloaded
from the Human Protein Reference Database Copyright©2002-09, Johns Hopkins University and The Institute of
Bioinformatics (Additional file 3), to use as a dictionary
file. The file contains 19,327 unique IDs. The format con-
sists of the HPRD id, gene symbol, RefSeq id, and aliases
(separated by semi-colons). The gene symbol will be used
to create a consensus name for all other aliases found. The
entities were mapped via another Python script.
Scoring
Counts were performed at the abstract level, where a men-
tion of a given biomarker was assigned a count of 1, re-
gardless of the frequency of mentions within the abstract.
Each z-score corresponds to a point in a normal distri-
bution and can be associated to its deviation from the
mean. Z-scores were computed as follows:
Briefly, from Al-Mubaid [16], S1 is the positive set of
abstracts (i.e. disease/biofluid), S1 = {A1, A2, …, An}. A is
a given abstract, Sp is the set of proteins (markers) men-
tioned in the dictionary found in the positive set S1, Sp =
{P1, P2, …, Pm}. S2 is the negative set of abstracts.
For each protein (marker) Pi in Sp, compute the docu-
ment frequency (df ) of Pi in both sets S1 and S2 as:
df1 Pið Þ ¼ number of S1 documents in which Pi
is mentioned;
df2 Pið Þ ¼ number of S2 documents in which Pi
is mentioned;
dft Pið Þ ¼ df1 Pið Þ þ df2 Pið Þ:
For each protein in the set Sp compute an expectation
(ex) value and an evidence (ev) value as:
ex Pið Þ ¼ dft Pið Þ= S1 þ S2j j½   S1j j; and
ev Pið Þ ¼ df1 Pið Þ
Ex measures expected number of mentions of Pi in the
abstracts in set S1; ev measures actual number of S1 ab-
stracts that Pi has appeared in. The larger the difference in
observed and expected document frequencies, ev(Pi) – ex
(Pi), the more likely that Pi and the disease are significantly
associated.
The difference is normalized by:
f Pið Þ ¼ ev Pið Þ−ex Pið Þ=dft Pið Þ:
And the z-score is calculated by:
Z Pið Þ ¼ f Pið Þ−mean fð Þ½ =SD fð Þ
where mean(f ) is the mean of all f values of all pro-
teins of Sp and SD(f ) is the standard deviation of the
f values.
A threshold value of 1.0 was established as a signifi-
cance cut-off (see Figure 2). These z-score values will be
Figure 2 Number of markers identified across the range of
possible Z-scores. Decreasing the Z-score threshold allows for
more significant markers to be identified.
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forts (Additional file 4 and Additional file 5).
Verification of relationships
One possible method of verification is to remove from the
abstract pool, ‘verification documents’ (ones specifically
pertaining to a disease-protein relationship), and use them
for subsequent verification [16]. Our method allows these
abstracts to remain in the pool, and verification is per-
formed by comparing our results to a combined disease
biomarker list (Additional file 6: Table S1 & Additional
file 7: Table S2). The list was created using the following
sources: OMIM [29] (O in table); http://www.ncbi.nlm.
nih.gov/omim/), a cancer gene annotation system for
cancer genomics [32] (CAGE(C); http://mgrc.kribb.re.kr/
cage/pageHome.php?m=hm), NCBI’s Genes & Disease
[33] ((G); http://www.ncbi.nlm.nih.gov/books/NBK22183/),
NCI’s Early Detection Research Network [34] (EDRN (E);
http://edrn.nci.nih.gov/), an expert provided list (X) of vali-
dated cancer markers [35], and a recently released breast
cancer paper [36] (P). Markers that are present in at least
one of these lists, as well as in our dictionary were consid-
ered verified. The list for breast cancer was compiled using
OMIM, CAGE, Genes & Disease, the expert provided list,
and the previously mentioned paper. The lung cancer list
was compiled from OMIM, CAGE, EDRN, and the expert
provided list.True positive rate determination
Negative abstracts were utilized to initially eliminate
some false positives. However, it is more likely than not,
that this process alone will not completely eliminate all
false positives.
In processing the abstracts, it was apparent that even-
tually manual examination of abstracts would be re-
quired for result verification. The abstract PubMed
identifier of every possible instance of every biomarker
mention accompanied each biomarker, allowing for
manual tracking and further verification of our results.
Relevant abstracts were investigated further. Three cri-
teria were used for a pass/fail outcome. Abstracts were
examined for mentions of biomarker, disease, and bio-
fluid. All three criteria were required to be acceptable,
and synonyms and/or root words were deemed adequate
(e.g. biliary instead of bile).
Results
Positive and negative sets
Table 1 describes the number of relevant abstracts ob-
tained from the PubMed searches. Fourteen biofluids
were evaluated. From this table, blood, plasma, and
serum returned the most positive and negative abstracts
from both breast and lung cancer queries. Over five mil-
lion total abstracts were examined.
Known markers per biofluid
Our known marker lists are combinations of several
‘biomarker lists’ obtained from well-known databases.
The known breast cancer marker list contains 211 gene
symbols that mapped to our dictionary (Additional file
6: Table S1; 159 found in this exercise), and the known
lung cancer marker list has 209 markers that mapped
to our dictionary (Additional file 7: Table S2; 145 found
in this exercise). Known marker results presented in
Table 2 were obtained by identifying putative biomarkers
with a z-score exceeding the significance threshold
(>1.0), and confirming the gene symbol in our known
disease biomarker list. Table 2 also summarizes the bio-
fluids that produced markers with significant z-scores
and/or the number of known markers found for breast
and lung cancer.
Z- score threshold optimization
We chose an appropriate threshold for z-score based on
empirical findings. As shown in Figure 2 which is a plot
of the number of known markers and new markers
(log10) based on the z-score threshold which was varied
between 1 and 4 in increments of 0.5. Based on this we
chose a non-stringent z-score threshold of 1.0 which al-
lows us to identify the maximum number of known and
new markers.
Table 2 Number of markers identified for each disease-biofluid combination
Breast
Cancer
Total number of
markers found
Known markers
found (211 possible)
Markers producing a
significant z-score (>1.0)
Known markers with a
significant z-score
New markers with a
significant z-score
% new
discoveries
Bile 200 26 58 7 51 87.93
Blood 2084 150 196 9 187 95.41
Breastmilk
CSF 116 8 18 0 18 100.00
Mucus 63 13 8 3 5 62.50
Plasma 1002 88 100 5 95 95.00
Saliva 73 9 10 2 8 80.00
Semen 35 3 6 0 6 100
Serum 1327 106 145 6 139 95.86
SF 21 0 4 0 4 100.00
Stool 68 8 7 3 4 57.14
Sweat 123 15 28 3 25 89.29
Tears 26 2 3 0 3 100.00
Urine 310 32 38 3 35 92.11
Lung
Cancer
Total number of
markers found
Known markers
found (211 possible)
Markers producing a
significant z-score (>1.0)
Known markers with a
significant z-score
New markers with a
significant z-score
% new
discoveries
Bile 167 17 25 1 24 96.00
Blood 1863 141 152 7 145 95.39
Breastmilk 77 15 11 2 9 81.82
CSF 106 7 11 1 10 90.91
Mucus 276 27 73 10 63 86.30
Plasma 843 75 65 4 61 93.85
Saliva 53 3 7 1 6 85.71
Semen 11 2 0 0 0 0
Serum 1109 100 103 3 100 97.09
SF 13 2 3 0 3 100.00
Stool 45 2 5 0 5 100.00
Sweat 44 5 4 0 4 100.00
Tears 12 0 1 0 1 100.00
Urine 256 30 56 6 50 89.29
Known markers were determined by identification of the given gene symbol in our known biomarker lists (Additional file 6: Table S1 or Additional file 7: Table S2).
Significant markers had a z-score >1.0.
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disease-biofluid
Table 2 shows the breakdown of the number of markers
found by our method. In most biofluids, the number found
in breast cancer outnumbers the number found in lung
cancer, with the exceptions being breastmilk (removed
from our breast cancer examination due to both positive
and negative search terms containing the root ‘breast’) and
mucus (greater association with respiratory system).
Known markers found significant vs. non-significant
While the truth is unknown as to the members of the
comprehensive pool of breast or lung cancer biomarkers,
and thus a true positive value cannot be obtained,estimates can be made. Although these numbers are not
shown, one can easily calculate the percentage of known
markers identified as significant vs. not-significant using
the counts from Table 2.
For breast cancer, percentages range from 5% in
plasma and serum to 37.5% in stool (for biofluids with
known-significant markers; non-zero). In lung cancer
the range is from 3% in serum to 37% in mucus.
Newly discovered markers found significant vs. non-significant
The percentage of newly discovered markers (markers
not found in known marker list) that were found to be
significant vs. the percentage that were identified but
not found to be significant was calculated.
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to 29.3% in bile (for biofluids with known-significant
markers; non-zero). In lung cancer the range is from 7.9%
in plasma to 27.2% in synovial fluid.
Potential marker biofluid specificity
Biomarker commonality and specificity was sought
across biofluids. This was a significant finding in that we
have not seen many potential biomarker comparisons
across more than a few biofluids. Additional file 8: Table
S3 shows the known + significant biomarkers within
biofluids for breast and lung cancer.
A total of 21 known + significant markers were identi-
fied for breast cancer. Nine biofluids produced known
ID’s with significant scores. A breakdown of this list
shows that 14 are only identified in combination with
one biofluid, 3 with two biofluids, 1 with 3 biofluids
(ERBB2; mentioned blood, plasma, and serum), 1 with 4
biofluids (NCOA3; mentioned in bile, blood, plasma,
and serum), 1 with 6 biofluids (BRCA2; mentioned in
bile, blood, mucus, saliva, serum, and sweat), and 1 with
7 biofluids (BRCA1; mentioned in blood, mucus, plasma,
saliva, serum, sweat, and urine abstracts).
A total of 26 known + significant putative markers
were identified for lung cancer. Eight biofluids produced
known ID’s with significant scores. A breakdown of this
list shows that 21 are only mentioned in combination
with one biofluid, 3 with two biofluids, 1 with 3 biofluids
(EML4; mentioned in blood, mucus, and serum), and 1
with 4 biofluids (KRAS; mentioned in blood, breastmilk,
mucus, and serum).
Manual verification of findings
A manual check of relevant abstracts was performed to
ensure the reliability of our results. Each relevant
PubMed abstract was manually examined to verify the
biomarker mentioned. The results of this manual verifi-
cation can be seen in Additional file 1: Table S4. Four
known biomarkers (CHEK2 in both plasma and urine,
CDKN1B, PCNA, and THBS1) were identified as false
positives (red) in our breast cancer list, and seven
(KRAS, GDNF in both breastmilk and plasma, MYCL1
in both blood and serum, CD40LG, CGA, CTAG1A,
ERCC6, and HRAS) in our lung cancer list. KRAS is in-
teresting in that it produced a false positive in associ-
ation with breastmilk, but had verified positive findings
in associations with blood, mucus, and serum.
True positive rate estimation of new discoveries
Manual verification allowed us to calculate the true posi-
tive rates across the biofluids-diseases. The results found
in Additional file 1: Table S4 show an average error rate
for breast cancer of 12.5%, and an average lung cancer
error rate of 29.41%. From these calculations, one canconclude that 87.5% of the breast cancer new discoveries
would be true positives, and 70.59% of the lung cancer
new discoveries would be true positives.
Discussion
We have presented a method to determine the possibil-
ity of relatedness between potential biomarkers in bio-
fluids and disease (breast and lung cancers), using
positive and negative sets of abstracts and a z-score.
Error exists in ABNER’s [31] tagging, our dictionary
consensus, and possibly anywhere manual processing of
the data occurs. Negation was not addressed at this time.
A potential dictionary problem was identified in that
some members of a protein family had a generic alias in
common. This led to results such as ceacam5 and cea-
cam8 both being identified for the CEA alias. Adding
another unique ID such as “ceacam_family” to account
for this double counting was considered, however it was
decided to let the counts stand, as there may be double
counting elsewhere in the dictionary of which we are
unaware.
In some situations a potential biomarker may need to
only be mentioned in one negative set abstract to exhibit
non-significance by our method. As disease-specific po-
tential markers are sought, common biomarkers impli-
cated in several diseases may not reach a significant
score by our method because of their mention in ab-
stracts describing other diseases including other types of
cancer.
A requirement for potential biomarkers to appear in
different abstracts was not applied. Several biomarker
mentions may come from the same abstract. Similarly,
there was not a requirement for different biofluids to ap-
pear in different abstracts. One biomarker discussed in
association with more than one biofluid may appear in
the list for each biofluid.
The number of known cancer biomarkers found but
deemed not significant was reported. The results may be
due to the way the negative search space was defined. It
is possible that abstracts of other cancers or diseases
exist in our negative set, and thus any biomarker men-
tioned in association with any other disease would neg-
ate our positive findings for breast and/or lung cancer.
Databases used for verification are probably far from
being complete, which could be why our list of known +
significant biomarkers is smaller than expected. Another
explanation could be that certain markers just may not
be found in a given biofluid. We will work to improve
our verification methods over time.
Lastly, only abstracts were examined in this work. Ob-
viously, full text examination would produce more find-
ings as well as more confidence in the findings, but
access to full text remains a limiting factor for all text-
mining researchers.
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We have presented a method that utilizes literature min-
ing to create a list of documented putative biomarker-
biofluid relationships for breast and lung cancer. Over 5
million abstracts were analyzed for biomarker-disease
associations. These abstract sets were further stratified
among 14 biofluids. Some false positives were initially
eliminated by examining negative sets of abstracts and
establishing a threshold z-score. New knowledge pertain-
ing to breast and lung cancer is presented in the forms
of known disease biomarker lists; ranked, newly discov-
ered biomarker-disease-biofluid relationships; and bio-
marker specificity across biofluids. The relationships
obtained from literature mining were verified by com-
parison to well-known published databases. Manual
examination of abstracts allowed for known relationship
verification and true positive rate calculations. On aver-
age, we can expect an 87.5% true positive rate for our
breast cancer new discoveries, and a 71.59% true positive
rate for our lung cancer new discoveries.
Future work in this area will include further automation
of our semi-automated process, applying our method to
other diseases, assembling a disease database to make our
z-score findings available to others, as well as converting
our z-score values into prior probabilities for use as in-
formative priors in Bayesian disease modeling.Additional files
Additional file 1: Table S4. Manually verified biomarker table.
Biomarker specific abstracts were manually examined for accuracy.
Abstracts were examined for mentions of biofluid, disease, and
biomarker. Lack of any one term resulted in a ‘false positive’ result.
Additional file 2: SupplementaryBiofluidTable.
Additional file 3: SupplementaryProteinlist.
Additional file 4: SupplementaryBCResults.
Additional file 5: SupplementaryLCResults.
Additional file 6: Table S1. List of breast cancer identifiers.
Additional file 7: Table S2. List of lung cancer identifiers.
Additional file 8: Table S3. Identification of the significant
validated potential markers found to be in common to several
biofluids or biofluid specific for breast and lung cancer. Biomarkers
highlighted in yellow are either breast cancer markers found in the list of
validated lung cancer biomarkers (Additional file 7: Table S2), or lung
cancer markers found in the list of validated breast cancer biomarkers
(Additional file 6: Table S1). It is doubtful that these markers are disease
specific. CDH1 is the only found biomarker in both cancer lists.Competing interests
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